Transcatheter Aortic Valve Replacement Outcomes of Patients With Moderate or Severe Mitral Regurgitation by Toggweiler, Stefan et al.
Journal of the American College of Cardiology Vol. 59, No. 23, 2012
© 2012 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00CLINICAL RESEARCH Interventional Cardiology
Transcatheter Aortic Valve Replacement
Outcomes of Patients With Moderate or Severe Mitral Regurgitation
Stefan Toggweiler, MD,* Robert H. Boone, MD,* Josep Rodés-Cabau, MD,†
Karin H. Humphries, PHD,* May Lee, PHD,* Luis Nombela-Franco, MD,† Rodrigo Bagur, MD,†
Alexander B. Willson, MBBS,* Ronald K. Binder, MD,* Ronen Gurvitch, MBBS,*
Jasmine Grewal, MD,* Robert Moss, MD,* Brad Munt, MD,* Christopher R. Thompson, MD,*
Melanie Freeman, MBBS,* Jian Ye, MD,* Anson Cheung, MD,* Eric Dumont, MD,†
David A. Wood, MD,* John G. Webb, MD*
Vancouver, British Columbia, and Quebec City, Quebec, Canada
Objectives The aim of this study was to evaluate the impact of mitral regurgitation (MR) on outcomes after transcatheter
aortic valve replacement (TAVR) and the impact of TAVR on MR.
Background Little is known of the influence of MR on outcomes after TAVR.
Methods The outcomes of patients with mild or less (n  319), moderate (n  89), and severe (n  43) MR were evalu-
ated after TAVR at 2 Canadian centers.
Results Patients with moderate or severe MR had a higher mortality rate than those with mild or less MR during the 30
days after TAVR (adjusted hazard ratio: 2.10; 95% confidence interval: 1.12 to 3.94; p  0.02). However, the
mortality rates after 30 days were similar (adjusted hazard ratio: 0.82; 95% confidence interval: 0.50 to 1.34;
p  0.42). One year after TAVR, moderate MR had improved in 58%, remained moderate in 17%, and worsened
to severe in 1%, and 24% of patients had died. Severe MR had improved in 49% and remained severe in 16%,
and 35% of patients had died. Multivariate predictors of improved MR at 1 year (vs. unchanged MR, worse MR,
or death) were a mean transaortic gradient 40 mm Hg, functional (as opposed to structural) MR, the absence
of pulmonary hypertension, and the absence of atrial fibrillation.
Conclusions Moderate or severe MR in patients undergoing TAVR is associated with a higher early, but not late, mortality
rate. At 1-year follow-up, MR was improved in 55% of patients with moderate or severe MR at baseline. Improve-
ment was more likely in patients with high transaortic gradients, with functional MR, without pulmonary hy-
pertension and without atrial fibrillation. (J Am Coll Cardiol 2012;59:2068–74) © 2012 by the American
College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2012.02.020Mitral regurgitation (MR) is present in most patients
with severe aortic stenosis. In patients undergoing surgi-
cal aortic valve replacement, the reported prevalence of
moderate or severe MR ranges from 13% to 74% (1–3).
Such patients often undergo concomitant mitral valve
repair or replacement.
Similarly, large series have reported moderate or severe
MR in 22% to 48% of patients undergoing transcatheter
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2012, accepted February 27, 2012.aortic valve replacement (TAVR) (4–10), although in this
setting, MR is typically left untreated. In fact, patients with
severe MR have generally been excluded from formal
evaluation, and outcomes in patients with MR have not
been a focus of evaluation (11–13). Consequently, little is
known about the impact of MR on clinical outcomes after
TAVR and the impact of TAVR on MR (12,14).
Methods
Study population. Between January 2005 and July 2010, a
total of 478 patients underwent TAVR for the treatment of
severe symptomatic aortic stenosis at 2 Canadian centers,
St. Paul’s Hospital (Vancouver, British Columbia, Canada),
and the Quebec Heart and Lung Institute (Quebec City,
Quebec City, Canada), with the balloon expandable Cribier-
Edwards, Edwards SAPIEN, or SAPIEN XT valve (Edwards
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June 5, 2012:2068–74 TAVR in Patients With Mitral RegurgitationLifesciences, Irvine, California). Patients were excluded from
analysis if they had mitral valve prostheses or received a non-
balloon-expandable valves, leaving a final study population of 451
patients. All patients provided written informed consent for the
procedure.
Data collection and definitions. Clinical and echocardio-
graphic data were prospectively entered into a dedicated
database at baseline, hospital discharge, 30 days, and annu-
ally. Transthoracic echocardiography was performed before
TAVR, at a median of 3 days after TAVR (but before
discharge), and after 1 year by senior echocardiographers
according to the guidelines of the American Society of
Echocardiography (15). MR severity was graded as none or
trivial, mild, moderate, or severe according to the American
College of Cardiology/American Heart Association/
European Society of Cardiology recommendations, inte-
grating structural, Doppler, and quantitative parameters
(16). Left ventricular ejection fraction (LVEF) was calcu-
lated using the biplane Simpson’s method. The severity of
mitral annular calcification was graded according to Nair et
al. (17). MR was classified on the basis of transthoracic and,
in case of ambiguity, transesophageal echocardiography as
predominantly functional or ischemic (no or minor associ-
ated pathology of the mitral valve leaflets, annulus, and
chordate or papillary muscles on echocardiography) or
predominantly structural or organic. Pulmonary hyperten-
sion was defined as a pulmonary artery systolic pressure
(PASP) 60 mm Hg, as estimated by Doppler echocardi-
ography or measured by cardiac catheterization (14). Por-
celain aorta was defined as an extensive circumferential
calcification of the thoracic aorta, as assessed by computed
Baseline CharacteristicsTable 1 Baseline Characteristics
Mild or Less M
(n  319)
Age (yrs) 81 9
Female 163 (51%)
Coronary artery disease 230 (73%)
Previous myocardial infarction 134 (42%)
Previous open-heart surgery 109 (34%)
Previous PCI 93 (29%)
Previous cerebrovascular accident 66 (21%)
COPD 93 (29%)
Diabetes 97 (30%)
Hypertension 252 (79%)
GFR 60 ml/min 194 (61%)
Pulmonary hypertension 42 (13%)
Porcelain aorta 53 (17%)
Atrial fibrillation 96 (30%)
NYHA functional class III or IV 283 (88%)
STS risk score (%) 7.5 (5.0–10.7)
Mean gradient (mm Hg) 43 17
Aortic valve area (cm2) 0.64 0.17
LVEF (%) 60 (50–65)
Values are mean  SD, n (%), or median (interquartile range).
COPD  chronic obstructive pulmonary disease; GFR  glomerular filtr
regurgitation; NYHA  New York Heart Association; PCI  percutaneous corotomography and/or fluoroscopy
(14). Patient–prosthesis mismatch
was defined as an indexed effective
orifice area0.85 cm2/m2 (18,19).
ne-year follow-up was available
n 131 of 132 patients (99%) with
oderate or severe MR.
tatistical analysis. Continuous
ariables are expressed as mean 
D or as median (interquartile
ange) in cases of skewed distri-
utions. Categorical variables are
xpressed as frequencies and per-
ents. Differences between inde-
endent groups were tested using
he Kruskal-Wallis test for 3
roups and the Wilcoxon rank sum test and t test for
continuous variables. In cases in which the samples were
paired, the Wilcoxon signed rank or paired t test was used.
ategorical variables were compared using the chi-square
est. Survival rates at 30 days and at 1 and 2 years were
stimated and graphed using the Kaplan-Meier method.
ariables included in the baseline characteristic and proce-
ural tables were tested for association with 2-year survival
ates and included in the model if they were univariately
ignificant at 0.25 to estimate the risk-adjusted hazard ratio
HR). A Cox regression model was used to estimate HRs
nd 95% confidence intervals (CIs) to compare the patients
ith moderate or severe MR with those with mild or less
R for all-cause mortality. On the basis of Schoenfeld
esidual plots, the effect of the MR groupings appeared to
Moderate MR
(n  89)
Severe MR
(n  43) p Value
82 7 84 8 0.03
52 (58%) 24 (56%) 0.44
66 (74%) 35 (81%) 0.46
47 (53%) 26 (61%) 0.03
37 (42%) 21 (49%) 0.11
20 (23%) 16 (37%) 0.20
19 (21%) 7 (17%) 0.81
21 (24%) 11 (26%) 0.55
21 (24%) 9 (21%) 0.24
70 (79%) 27 (63%) 0.06
61 (69%) 30 (70%) 0.32
18 (20%) 15 (35%) 0.01
27 (30%) 8 (19%) 0.02
35 (39%) 29 (67%) 0.01
78 (88%) 41 (95%) 0.37
8.1 (6.3–12.2) 9.7 (6.3–12.1) 0.02
44 16 43 17 0.95
0.60 0.15 0.59 0.14 0.02
57 (45–60) 50 (40–60) 0.01
Abbreviations
and Acronyms
CI  confidence interval
HR  hazard ratio
LVEDD  left ventricular
end-diastolic diameter
LVEF  left ventricular
ejection fraction
MR  mitral regurgitation
OR  odds ratio
PASP  pulmonary artery
systolic pressure
TAVR  transcatheter
aortic valve replacementRation rate; LVEF  left ventricular ejection fraction; M
nary intervention; STS  Society of Thoracic Surgeons.R  mitral
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TAVR in Patients With Mitral Regurgitation June 5, 2012:2068–74change at 30 days, so time-varying coefficients were in-
cluded in the regression model to account for the differences
in the effect of the MR grouping up to 30 days and after 30
days to 2 years. Odds ratios (ORs) and 95% CIs were
calculated for multivariate predictors of improved MR at
1-year follow-up. Variables were included if they were
univariately significant at 0.25 and removed in a stepwise
selection process on the basis of a significance level of 0.10.
Analyses were conducted using SAS version 9.2 (SAS
Institute Inc., Cary, North Carolina) and tested using
2-sided tests at a significance level of 0.05.
Results
A total of 451 patients were analyzed. Valves implanted
were the Cribier-Edwards in 56 (12%), the Edwards
SAPIEN in 270 (60%), and the SAPIEN XT in 115 (28%)
patients. At baseline, MR was mild or less in 319 patients
(71%), moderate in 89 (20%), and severe in 43 (10%).
As shown in Table 1, moderate or severe MR was
ssociated with increasing age, atrial fibrillation, prior myo-
ardial infarction, porcelain aorta, a lower LVEF, smaller
ortic valve area, and a higher Society of Thoracic Surgeons
isk score.
rocedural outcomes and survival. Access route, prosthe-
sis size, and procedural complications were similar regard-
less of the severity of MR (Table 2). Survival in patients
with mild or less, moderate, and severe MR at baseline was
92.5%, 86.5%, and 83.7% at 30 days; 79.0%, 76.2%, and
64.5% at 1 year; and 66.2%, 67.9%, and 58.5% at 2 years,
respectively (Fig. 1). Compared with patients with mild or
less MR, those with moderate or severe MR had a higher
mortality rate during the first 30 days (unadjusted HR: 2.04;
95% CI: 1.11 to 3.74; p  0.02; and adjusted HR: 2.10;
95% CI: 1.12 to 3.94; p  0.02) but no difference after 30
ays (unadjusted HR: 0.94; 95% CI: 0.58 to 1.51; p 0.80;
nd adjusted HR: 0.82; 95% CI: 0.50 to 1.34; p  0.42)
Procedural and 30-Day OutcomesTable 2 Procedural and 30-Day Outcomes
Mild or Less MR
(n  319)
Access route
Transfemoral 163 (51%)
Transapical 156 (49%)
Prosthesis size (mm)
23 131 (41%)
26 186 (58%)
29 2 (1%)
Mean gradient (mm Hg) 11 5
Aortic valve area (cm2) 1.6 0.4
Major stroke 7 (2%)
New permanent pacemaker 21 (7%)
Coronary occlusion 5 (2%)
Mortality 24 (8%)
Values are n (%) or mean  SD.
MR  mitral regurgitation.Table 3).ew York Heart Association functional class. At 1-year
ollow-up, New York Heart Association functional class
ad generally improved, with only 6% of patients (5 of 88)
ith moderate MR and 5% of patients (2 of 43) with severe
R in class III or IV (Fig. 2).
R grade. Changes over time in MR severity are shown in
igure 3.
Moderate MR
(n  89)
Severe MR
(n  43) p Value
0.07
41 (46%) 29 (67%)
48 (54%) 14 (33%)
0.42
43 (48%) 14 (33%)
46 (52%) 29 (67%)
0 (0%) 0 (0%)
11 5 10 4 0.45
1.5 0.3 1.5 0.4 0.12
3 (3%) 1 (2%) 0.82
8 (9%) 0 (0%) 0.14
1 (1%) 0 (0%) 0.69
12 (14%) 7 (16%) 0.07
Figure 1
Kaplan-Meier Curves for All-Cause Mortality
in Patients With Mild or Less, Moderate,
and Severe MR at Baseline
Survival in patients with mild or less, moderate, and severe mitral regurgitation
(MR) at baseline was 92.5%, 86.5%, and 83.7% at 30 days; 79.0%, 76.2%,
and 64.5% at 1 year; and 66.2%, 67.9%, and 58.5% at 2 years, respectively.
TAVR  transcatheter aortic valve replacement.
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June 5, 2012:2068–74 TAVR in Patients With Mitral RegurgitationAfter TAVR, moderate MR improved in 62%, remained
moderate in 27%, and worsened to severe in 5%. At 1 year,
MR had improved in 58%, remained moderate in 17%, and
worsened to severe in 1%, and 24% of patients had died. In
patients with severe MR at baseline, MR improved in 60%
and remained severe in 33% after TAVR. At 1 year, MR
had improved in 49% and remained severe in 16%, and 35%
of patients had died (Fig. 3).
Predictors of improved MR. Table 4 compares baseline
and procedural characteristics in patients with improved
MR with those with unchanged or worse MR or patients
who died before 1-year follow-up. For stepwise multivariate
analysis, absence of atrial fibrillation, a mean gradient 40
mm Hg, PASP 60 mm Hg, LVEF 50%, mitral annular
calcification grade 2 or 3, and the presence of functional MR
(all with p values 0.25) were included in the initial step of
the model-building process. Only the following significant
predictors remained in the final model: mean transaortic
gradient  40 mm Hg (OR: 2.92; 95% CI: 1.20 to 6.60;
p  0.01), the presence of functional MR (OR: 2.85; 95%
CI: 1.27 to 6.39; p  0.01), the absence of pulmonary
hypertension (OR: 2.57; 95% CI: 1.07 to 6.16; p  0.03),
and the absence of atrial fibrillation (OR: 2.55; 95% CI:
1.19 to 5.46; p  0.02) (Table 5).
HRs for Moderate or Severe Versus Mild or Less MRTable 3 HRs for Moderate or Severe Versus ild or Less MR
HR (95% CI) p Value
Unadjusted
30 days 2.04 (1.11–3.74) 0.02
30 days 0.94 (0.58–1.51) 0.94
Risk adjusted
30 days 2.10 (1.12–3.94) 0.02
30 days 0.82 (0.50–1.34) 0.42
The risk-adjusted HRs were adjusted for Society of Thoracic Surgeons risk score, mean gradient,
porcelain aorta, site, access route, New York Heart Association functional class, atrial fibrillation,
prior cerebrovascular accident, kidney function, pulmonary hypertension, chronic obstructive
pulmonary disease, and sex.
CI  confidence interval; HR  hazard ratio; MR  mitral regurgitation.
Figure 2 NYHA Functional Class at Baseline and 1-Year
Follow-Up in Patients With Moderate or Severe MR
At 1-year follow-up, New York Heart Association (NYHA) functional class had
improved, with only 6% of patients with moderate mitral regurgitation (MR) and
5% of patients with severe MR in NYHA class III or IV.tLVEF, left ventricular diameter, and PASP. At 1 year,
patients with moderate or severe MR had significant im-
provements in LVEF, left ventricular end-diastolic diameter
(LVEDD), and PASP, but 28% of the patients had died. In
patients with moderate MR at baseline, median LVEF
increased from 57% (interquartile range: 45% to 60%) to
60% (interquartile range: 55% to 65%) (p  0.03), mean
LVEDD dimension decreased from 49  8 mm to 46  6
mm (p  0.01), and mean PASP decreased from 49  8
mm Hg to 41  11 mm Hg (p  0.01). In patients with
severe MR at baseline, median LVEF increased from 50%
(interquartile range: 40% to 60%) to 60% (interquartile
range: 54% to 65%) (p  0.01), mean LVEDD decreased
from 53  7 mm to 51  6 mm (p  0.17), and mean
PASP decreased from 55  18 mm Hg to 49  13 mm Hg
p  0.01).
iscussion
oderate or severe MR in patients undergoing TAVR was
ssociated with reduced survival. The mortality rate was higher
uring the first 30 days but not thereafter. The 30-day
ortality rate in patients with moderate or severe MR was
pproximately double that in patients with no or mild MR, but
ortality rates were similar from 30 days up to 2 years. MR
iminished in 61% of patients with moderate or severe MR at
aseline after TAVR. At 1-year follow-up MR, had improved
n 55%, remained unchanged in 16%, and worsened in 1%; the
emaining 28% had died. LVEF and LVEDD had improved
t 1-year follow-up, suggesting positive remodeling. Patients
ith high transaortic gradients, with functional (as opposed to
tructural) MR, without pulmonary hypertension, and without
trial fibrillation were more likely to have reductions in MR at
-year follow-up.
urvival. From published surgical research, it is known
Figure 3 Degree of MR After TAVR and at 1-Year Follow-Up
in Patients With Moderate or Severe MR at Baseline
One year after transcatheter aortic valve replacement (TAVR), moderate mitral
regurgitation (MR) had improved by 1 grade in 58% of patients, remained the
same in 17%, and worsened in 1%. Severe MR had improved by 1 grade in
49% and remained severe in 16%.hat combining mitral with aortic valve surgery is associated
(
p
1.
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TAVR in Patients With Mitral Regurgitation June 5, 2012:2068–74with increased postoperative mortality and morbidity
(20,21). A few studies have reported the impact of untreated
MR on isolated surgical aortic valve replacement. Some
(1,22), but not all (23), found increases in morbidity and
mortality in patients with moderate MR. In contrast to
surgical aortic valve replacement, concurrent mitral valve
repair or replacement has not been an option in patients
undergoing TAVR, although new transcatheter mitral ther-
apies offer options in the future (24).
Limited information is available with regard to the
impact of MR on outcomes after TAVR. A Canadian
registry reported that severe MR was present in 17% of
patients who died within 30 days after TAVR but only 7%
of those who survived (14). The Italian CoreValve
Medtronic, Inc., Minneapolis, Minnesota) registry re-
orted that grade 3 or 4 MR was present in 13.2% of
Baseline Characteristics of Patients With ModeWith Reduced and Unchanged or WorsTable 4 B s line Ch racteristics of PatientBaseline With Reduced and Unchan
Reduced MR
(n  71)
Age (yrs) 83 6
Female 43 (61%)
Coronary artery disease 52 (73%)
Previous myocardial infarction 41 (58%)
Previous open-heart surgery 32 (45%)
Previous cerebrovascular accident 14 (20%)
COPD 18 (25%)
Hypertension 55 (78%)
GFR 60 ml/min 49 (69%)
Pulmonary hypertension 12 (17%)
Porcelain aorta 21 (30%)
Atrial fibrillation 27 (38%)
NYHA functional class III or IV 65 (92%)
STS risk score (%) 8.5 (6.3–12.1
Mean gradient 40 mm Hg 50 (70%)
Aortic valve area (cm2) 0.58 0.14
Ejection fraction 50% 18 (25%)
Functional MR 45 (64%)
MAC grade 2 or 3 29 (41%)
Transfemoral access 39 (55%)
Valve size 26 mm 37 (52%)
Patient–prosthesis mismatch 41 (59%)
Values are mean  SD, n (%), or median (interquartile range).
MAC  mitral annular calcification; other abbreviations as in Table
Multivariate Predictors ofReduced MR at 1-Year Follow-UpTable 5 Multivariate Predictors ofReduced MR at 1-Year Follow-Up
Multivariate Odds Ratio
(95% CI)
Multivariate
p Value
Pulmonary pressure 60 mm Hg 2.68 (1.09–6.58) 0.03
Absence of atrial fibrillation 2.55 (1.17–5.55) 0.02
Mean gradient 40 mm Hg 2.71 (1.19–6.18) 0.02
Functional MR 2.61 (1.15–5.93) 0.02
Variables initially included in the model were pulmonary artery systolic pressure 60 mm Hg,
absence of atrial fibrillation, mean transaortic gradient40 mm Hg, functional MR, mitral annular
calcification grade 2 or 3, and left ventricular ejection fraction 50%.
CI  confidence interval; MR  mitral regurgitation.patients who died but only 4.9% of those who survived at a
median of 69 days after the procedure (HR: 4.62) (12).
Interesting data come from the PARTNER (Placement of
Aortic Transcatheter Valves) studies suggesting that pa-
tients with moderate or severe MR may derive a large
benefit from TAVR compared with both medical manage-
ment and surgical aortic valve replacement (5,25). In the
PARTNER B study, subgroup analysis showed that the
number needed to treat to prevent 1 death at 1 year was 3 in
patients with moderate or severe MR, compared with 7 in
patients without. In the PARTNER A study, 1-year mor-
tality of patients with moderate or severe MR was 24.2%
after TAVR (similar to the 27.7% in our study) and as high
as 35% after surgical aortic valve replacement.
Predictors of MR reduction. In line with our study, the
absence of atrial fibrillation (26) and functional (as opposed
to structural) MR (27) have been identified as predictors for
reduction of MR in patients undergoing isolated surgical
aortic valve replacement. Left atrial size (3,28), left ventric-
ular mass index (28), mitral valve tenting area (26), left
ventricular fractional area change (29), and less mitral
annular calcification (28) have also been reported to predict
MR reduction after surgical aortic valve replacement.
Little information is available with regard to changes in
MR after TAVR. Durst et al. (30) reported improvement in
mild to moderate MR after TAVR with the SAPIEN valve
in 12 of 35 patients (34%). The absence of mitral annular
or Severe MR atMR at 1-Year Follow-Uph Mod ate o Severe MR at
or Worsened MR at 1-Year Follow-Up
Unchanged or Worsened MR
(n  59)
Univariate
p Value
82 8 0.26
33 (56%) 0.59
48 (81%) 0.27
32 (54%) 0.69
25 (42%) 0.76
12 (20%) 0.96
14 (24%) 0.83
41 (70%) 0.30
41 (70%) 0.95
21 (36%) 0.02
14 (24%) 0.45
37 (63%) 0.01
52 (88%) 0.52
8.4 (6.1–12.2) 0.87
30 (51%) 0.02
0.61 0.15 0.26
27 (46%) 0.02
28 (48%) 0.06
32 (54%) 0.13
29 (49%) 0.51
36 (61%) 0.31
24 (51%) 0.37rateen ds Wit
ged
)calcification was associated with improved MR. Tzikas et al.
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TAVR with the CoreValve prosthesis, improving in 6 of 10
patients (60%), remaining unchanged in 3 patients (30%),
and worsening in 1 patient (10%). A worse LVEF was
associated with reduced MR. It has been suggested that the
effects of the 2 transcatheter valves may differ because of a
possible increased risk of the longer CoreValve prosthesis
interfering with the anterior mitral leaflet apparatus (32).
Mechanisms of benefit. The severity of MR depends
primarily on regurgitant orifice area and the systolic pressure
gradient between the left ventricle and the left atrium (33).
After aortic valve replacement, MR is expected to diminish
immediately because of a reduction in afterload and may
diminish further in the mid and long terms, should positive
left ventricular remodeling occur (34). Reductions in left
ventricular volumes may lead to improved coaptation of the
leaflets. As shown in this and other (27,28) studies, MR
reduction may be less likely in patients with structural mitral
valve disease, such as might occur in the presence of
deformed leaflets or moderate or severe annular calcifica-
tion. Patient–prosthesis mismatch and prosthesis size were
not significant predictors of MR reduction in our study.
Study limitations. Our data represent the experience of 2
enters rather than outcomes of a clinical trial, and they are
elf-reported, with no external independent data adjudication.
hanges in LVEF, left ventricular diameter, and PASP may be
ubject to survivor bias and may therefore be overestimated.
onclusions
f left untreated, patients with severe aortic stenosis and
oncomitant moderate or severe MR have a very poor prog-
osis. TAVR procedural mortality is increased in patients with
dvanced MR. Nevertheless, these findings demonstrate late
unctional benefit in survivors and are consistent with, but do
ot prove, a possible late survival benefit. MR was reduced in
ore than one-half of patients at 1-year follow-up. Various
linical factors may assist in identifying which patients may
enefit from isolated aortic valve replacement. TAVR may be
reasonable strategy in carefully selected patients with com-
ined aortic and mitral valve disease.
Reprint requests and correspondence: Dr. John G. Webb, St.
Paul’s Hospital, 1081 Burrard Street, Vancouver, British Colum-
bia V6Z 1Y6, Canada. E-mail: john.webb@vch.ca.
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